Stefan Diem

4.1k total citations · 2 hit papers
31 papers, 2.6k citations indexed

About

Stefan Diem is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Stefan Diem has authored 31 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 9 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Stefan Diem's work include Cancer Immunotherapy and Biomarkers (21 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (6 papers). Stefan Diem is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (6 papers). Stefan Diem collaborates with scholars based in Switzerland, United Kingdom and Germany. Stefan Diem's co-authors include James Larkin, Lavinia Spain, Lukas Flatz, Martin Früh, Wolfram Jochum, Sabine Schmid, Arnoud J. Templeton, Diana Born, Martin Gore and Juan Martín-Liberal and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and Journal of the American Academy of Dermatology.

In The Last Decade

Stefan Diem

30 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

2017 690 citations Stefan Diem, Sabine Schmid et al. Lung Cancer profile →
Management of toxicities of immune checkpoint inhibitors

2016 660 citations Lavinia Spain, Stefan Diem et al. Cancer Treatment Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stefan Diem Switzerland	17	2.2k	629	625	294	292	31	2.6k
Lavinia Spain United Kingdom	15	1.9k 0.9×	646 1.0×	464 0.7×	304 1.0×	352 1.2×	61	2.4k
Osama E. Rahma United States	28	2.1k 1.0×	520 0.8×	1.0k 1.6×	485 1.6×	371 1.3×	113	2.9k
Ian M. Waxman United States	15	2.3k 1.0×	993 1.6×	717 1.1×	434 1.5×	159 0.5×	35	2.8k
Dwight H. Owen United States	22	1.4k 0.6×	651 1.0×	270 0.4×	289 1.0×	313 1.1×	110	1.9k
Leyre Zubiri United States	22	1.3k 0.6×	450 0.7×	329 0.5×	402 1.4×	177 0.6×	56	2.0k
Parisa Momtaz United States	14	1.5k 0.7×	362 0.6×	499 0.8×	353 1.2×	150 0.5×	40	1.8k
Miso Kim South Korea	25	1.2k 0.5×	710 1.1×	276 0.4×	292 1.0×	107 0.4×	87	1.7k
Susan C. Guba United States	22	1.3k 0.6×	784 1.2×	346 0.6×	675 2.3×	207 0.7×	49	2.4k
Wade T. Iams United States	21	1.4k 0.6×	718 1.1×	459 0.7×	806 2.7×	308 1.1×	95	2.2k
Lois Ayash United States	25	1.3k 0.6×	330 0.5×	451 0.7×	323 1.1×	232 0.8×	119	2.6k

Countries citing papers authored by Stefan Diem

Since Specialization

Citations

This map shows the geographic impact of Stefan Diem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Diem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Diem more than expected).

Fields of papers citing papers by Stefan Diem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Diem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Diem. The network helps show where Stefan Diem may publish in the future.

Co-authorship network of co-authors of Stefan Diem

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Diem. A scholar is included among the top collaborators of Stefan Diem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Diem. Stefan Diem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klümper, Niklas, Fiamma Berner, Annkristin Heine, et al.. (2022). C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 10(3). e004024–e004024. 53 indexed citations

Purde, Mette-Triin, Rebekka Niederer, Nikolaus B. Wagner, et al.. (2021). Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. Journal of Cancer Research and Clinical Oncology. 148(3). 647–656. 11 indexed citations

Spain, Lavinia, Lewis Au, James J. Clark, et al.. (2020). Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open. 5(4). e000585–e000585. 30 indexed citations

Ali, Omar Hasan, Fiamma Berner, Christoph Ackermann, et al.. (2020). Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. Cancer Immunology Immunotherapy. 70(2). 563–568. 6 indexed citations

Diem, Stefan, et al.. (2019). First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor. Journal of Cancer Research and Therapeutics. 17(1). 276–278. 1 indexed citations

Ali, Omar Hasan, David Bomze, Sandra S. Ring, et al.. (2019). BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. Journal of the American Academy of Dermatology. 82(4). 854–861. 76 indexed citations

Herbrand, Amanda K., Andreas M. Schmitt, Matthias Briel, et al.. (2019). Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open. 4(6). e000596–e000596. 4 indexed citations

Diem, Stefan, Mirjam Fässler, Omar Hasan Ali, et al.. (2018). Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Management and Research. Volume 10. 5537–5544. 2 indexed citations

Ali, Omar Hasan, Fiamma Berner, David Bomze, et al.. (2018). Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. European Journal of Cancer. 107. 8–14. 143 indexed citations

10.

Schmid, Sabine, Stefan Diem, Qiyu Li, et al.. (2018). Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunology Immunotherapy. 67(12). 1825–1832. 79 indexed citations

11.

Diem, Stefan, Sabine Schmid, Lukas Flatz, et al.. (2017). Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 111. 176–181. 690 indexed citations breakdown →

12.

Spain, Lavinia, Stefan Diem, Komel Khabra, et al.. (2016). Patterns of steroid use in diarrhoea and/or colitis (D/C) from immune checkpoint inhibitors (ICPI). Annals of Oncology. 27. vi374–vi374. 5 indexed citations

13.

Ali, Omar Hasan, Stefan Diem, Eva Markert, et al.. (2016). Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. OncoImmunology. 5(11). e1231292–e1231292. 99 indexed citations

14.

Spain, Lavinia, Stefan Diem, & James Larkin. (2016). Management of toxicities of immune checkpoint inhibitors. Cancer Treatment Reviews. 44. 51–60. 660 indexed citations breakdown →

15.

Morganstein, Daniel L., et al.. (2016). Thyroid abnormalities following the use of cytotoxic T‐lymphocyte antigen‐4 and programmed death receptor protein‐1 inhibitors in the treatment of melanoma. Clinical Endocrinology. 86(4). 614–620. 145 indexed citations

16.

Diem, Stefan, Fabienne Keller, Samia Abed Maillard, et al.. (2016). Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. Journal of Immunotherapy. 39(9). 379–382. 43 indexed citations

17.

Bowyer, Samantha, Prashanth Prithviraj, Paul Lorigan, et al.. (2016). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. British Journal of Cancer. 114(10). 1084–1089. 92 indexed citations

18.

Martín-Liberal, Juan, et al.. (2015). BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert Opinion on Pharmacotherapy. 16(9). 1285–1297. 22 indexed citations

19.

Joerger, Markus, Dieter Koeberle, Klazien Matter‐Walstra, et al.. (2014). Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. European Journal of Clinical Pharmacology. 70(6). 719–725. 24 indexed citations

20.

Diem, Stefan, et al.. (2013). EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report. Case Reports in Oncology. 6(2). 316–319. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact